A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumor (PNET)
Phase of Trial: Phase I/II
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Pazopanib (Primary) ; Temozolomide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- 25 Oct 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020.
- 25 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2019.
- 15 Mar 2016 Protocol amended as treatment arms changed from 1 to 5 as reported by ClinicalTrials.gov.